Aveo Patent-Cliff Exposure & CMS Drug Spending Portfolio
Aveo (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $126.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2039-01-01 |
| 2024 CMS Total Public Spend | $126.1M |
| 2024 Medicare Part D Spend | $118.9M |
| 2024 Medicaid Spend | $7.2M |
| California HCAI SB 17 Filings | 6 WAC filings (max 25.4% 2-yr change) |